Interestingly, a-CTLA4-TGFβRII was able to exhibit superior single agent activity against PD-L1-expressing tumors and the addition of a-PD1 antibody did not significantly enhance its antitumor efficacy in the breast cancer model. This evidence concerns the gene CTLA4 and breast cancer.